DGKI (diacylglycerol kinase iota) is a lipid kinase that converts diacylglycerol (DAG) into phosphatidic acid (PA), functioning as a molecular switch between two signaling pathways with opposing effects 12. The enzyme acts as a regulator of multiple biological processes, including potential roles in presynaptic signaling and neurotransmitter release during glutamate receptor-dependent long-term depression. DGKI negatively regulates Rap1 signaling by controlling DAG-mediated activation of RASGRP3. Clinically, DGKI has emerged as relevant to multiple diseases. Genetic variants show positive selection in polycystic ovary syndrome (PCOS) populations, suggesting evolutionary advantage despite the disorder's reproductive burden 3. In glioblastoma, DGKI methylation status serves as a biomarker for treatment response; selective DGKI demethylation enhances temozolomide sensitivity 4. DGKI is associated with obesity risk in genome-wide association studies 5 and specific learning disorders including dyslexia 67. In thyroid carcinoma, higher DGKI expression correlates with improved survival outcomes 8. Additionally, DGKI inhibition reduces airway smooth muscle cell proliferation relevant to asthma pathology 9, and blocking DGK enzymes enhances tumor-infiltrating lymphocyte function in cancer immunotherapy 10.